Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, Procept BioRobotics Corp (NASDAQ: PRCT) closed at $60.36 down -3.87% from its previous closing price of $62.79. In other words, the price has decreased by -$3.87 from its previous closing price. On the day, 0.6 million shares were traded. PRCT stock price reached its highest trading level at $63.87 during the session, while it also had its lowest trading level at $60.155.
Ratios:
For a deeper understanding of Procept BioRobotics Corp’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.44 and its Current Ratio is at 8.52. In the meantime, Its Debt-to-Equity ratio is 0.31 whereas as Long-Term Debt/Eq ratio is at 0.30.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on August 11, 2023, initiated with a Overweight rating and assigned the stock a target price of $42.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 03 ’24 when Nouri Alaleh sold 30,432 shares for $62.97 per share. The transaction valued at 1,916,428 led to the insider holds 62,472 shares of the business.
Krummel Thomas M sold 20,000 shares of PRCT for $1,200,000 on May 01 ’24. The Director now owns 45,631 shares after completing the transaction at $60.00 per share. On Mar 18 ’24, another insider, Zadno Reza, who serves as the President, CEO of the company, sold 5,391 shares for $48.83 each. As a result, the insider received 263,243 and left with 241,319 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRCT now has a Market Capitalization of 3103964672 and an Enterprise Value of 3086647552. For the stock, the TTM Price-to-Sale (P/S) ratio is 19.85 while its Price-to-Book (P/B) ratio in mrq is 11.75. Its current Enterprise Value per Revenue stands at 19.745 whereas that against EBITDA is -29.61.
Stock Price History:
The Beta on a monthly basis for PRCT is 0.99, which has changed by 1.1248732 over the last 52 weeks, in comparison to a change of 0.2537824 over the same period for the S&P500. Over the past 52 weeks, PRCT has reached a high of $65.00, while it has fallen to a 52-week low of $24.83. The 50-Day Moving Average of the stock is 18.88%, while the 200-Day Moving Average is calculated to be 49.04%.
Shares Statistics:
For the past three months, PRCT has traded an average of 571.74K shares per day and 912330 over the past ten days. A total of 50.77M shares are outstanding, with a floating share count of 49.01M. Insiders hold about 4.70% of the company’s shares, while institutions hold 88.50% stake in the company. Shares short for PRCT as of 1713139200 were 5357470 with a Short Ratio of 9.37, compared to 1710460800 on 4117825. Therefore, it implies a Short% of Shares Outstanding of 5357470 and a Short% of Float of 14.360000000000001.
Earnings Estimates
Procept BioRobotics Corp (PRCT) is presently subject to a detailed evaluation by 8.0 analysts, each offering their unique perspectives on its market standing.On average, analysts expect EPS of -$0.52 for the current quarter, with a high estimate of -$0.5 and a low estimate of -$0.56, while EPS last year was -$0.56. The consensus estimate for the next quarter is -$0.49, with high estimates of -$0.47 and low estimates of -$0.52.
Analysts are recommending an EPS of between -$1.86 and -$2.0 for the fiscal current year, implying an average EPS of -$1.93. EPS for the following year is -$1.49, with 9.0 analysts recommending between -$1.16 and -$1.69.
Revenue Estimates
A total of 9 analysts believe the company’s revenue will be $50.16M this quarter.It ranges from a high estimate of $50.99M to a low estimate of $49.6M. As of the current estimate, Procept BioRobotics Corp’s year-ago sales were $30.46MFor the next quarter, 9 analysts are estimating revenue of $53.92M. There is a high estimate of $55.1M for the next quarter, whereas the lowest estimate is $52.63M.
A total of 9 analysts have provided revenue estimates for PRCT’s current fiscal year. The highest revenue estimate was $214.67M, while the lowest revenue estimate was $213.11M, resulting in an average revenue estimate of $213.73M. In the same quarter a year ago, actual revenue was $136.19MBased on 9 analysts’ estimates, the company’s revenue will be $300.41M in the next fiscal year. The high estimate is $313M and the low estimate is $276.9M.
